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Abstract
The low density lipoprotein receptor-related protein-5 (LRP5), a co-receptor in the Wnt sig-
naling pathway, modulates bone mass in humans and in mice. Lrp5 knock-out mice have
severely impaired responsiveness to mechanical stimulation whereas Lrp5 gain-of-function
knock-in and transgenic mice have enhanced responsiveness to mechanical stimulation.
Those observations highlight the importance of Lrp5 protein in bone cell mechanotransduc-
tion. It is unclear if and how high bone mass-causing (HBM) point mutations in Lrp5 alter the
bone-wasting effects of mechanical disuse. To address this issue we explored the skeletal
effects of mechanical disuse using two models, tail suspension and Botulinum toxin-
induced muscle paralysis, in two different Lrp5 HBM knock-in mouse models. A separate
experiment employing estrogen withdrawal-induced bone loss by ovariectomy was also
conducted as a control. Both disuse stimuli induced significant bone loss in WT mice, but
Lrp5 A214V and G171V were partially or fully protected from the bone loss that normally
results from disuse. Trabecular bone parameters among HBMmice were significantly
affected by disuse in both models, but these data are consistent with DEXA data showing a
failure to continue growing in HBMmice, rather than a loss of pre-existing bone. Ovariec-
tomy in Lrp5 HBMmice resulted in similar protection from catabolism as was observed for
the disuse experiments. In conclusion, the Lrp5 HBM alleles offer significant protection from
the resorptive effects of disuse and from estrogen withdrawal, and consequently, present a
potential mechanism to mimic with pharmaceutical intervention to protect against various
bone-wasting stimuli.
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Introduction
Osteoporosis is a low-bone-mass disease resulting from impaired bone modeling or imbal-
anced bone remodeling, in which resorption outpaces apposition, resulting in bones that are
fragile and prone to fracture [1]. Osteoporotic fractures are associated with chronic pain,
decreased quality of life, and large financial cost. Pathological bone loss also occurs in patients
that are immobilized due to bed rest [2, 3], muscle paralysis [4, 5], or have decreased mechani-
cal loading to the bone [6]. In paraplegic patients, the disuse-induced bone loss leads to
increasing risk of fractures in the lower limbs with time [4].
The Wnt signaling cascade, which was initially characterized as a pathway involved in neu-
ral tube development, limb patterning, planar cell polarity, axon guidance, and cancer, has
more recently emerged as a key pathway mediating bone homeostasis [7–12]. Consequently,
there has been great interest in understanding whether and howWnt signaling perturbations
might be involved in the development of osteoporosis [13, 14]. Perhaps more importantly, this
pathway is currently being probed to elucidate whether pharmacologic manipulation of Wnt
signaling in bone might lead to additional and potentially more effective treatments for osteo-
porosis [15]. The interest in Wnt’s role in osteoporosis biology has extended to disuse osteopo-
rosis [16, 17], and work in this area has yielded promising results [18–20].
Wnt proteins interact with the surface receptors low density lipoprotein receptor-related
proteins 5 or 6 (LRP5, LRP6) and a family of co-receptors—the Frizzled proteins. Mutations in
LRP5 can lead to vastly different skeletal effects in humans, ranging from severely low bone
mass [14] to a very high bone mass (HBM) phenotype [21, 22]. LRP5 HBM-causing mutations
are of particular therapeutic interest as they may hold clues for effective treatments for osteo-
porosis and disuse-induced bone loss. The molecular mechanism by which these mutations
lead to high bone mass is becoming elucidated, and likely involves resistance to soluble LRP5/6
antagonists, including sclerostin, Dkk1, and Wise [10, 23–30].
We have recently found that mice harboring the G171V or A214V HBMmutations within
the Lrp5 coding sequence are resistant to the osteopenic effects of excessive sclerostin exposure,
but mice with the G171Vmutation exhibited greater resistance to excessive Dkk1 exposure that
did mice with the A214Vmutation [29]. Furthermore, we found that mechanical loading reduces
Sost expression, whereas forced overexpression of Sost prevents mechanically induced bone gain
[31, 32]. Conversely, increased expression of Sost is required for tail suspension-induced bone
loss [18]. In light of our previous observations that (1) the Lrp5 G171V and A214V mutations
protect against Sost-induced bone loss, and (2) Sost has an important role in mechanotransduc-
tion signaling, we hypothesized that the Lrp5 G171V and A214V HBM knock-in mice would be
resistant to bone loss under mechanically induced bone-wasting stimuli.
In this communication, we examine the role of Lrp5 HBMmutations in modulating the cat-
abolic effects of disuse, using two different disuse models. First, a hindlimb suspension model
was used, which suspends and unloads the hindlimbs, while allowing the forelimbs to maintain
contact with the cage floor. This method prevents ground reaction forces in the hindlimbs, and
has been used to model disuse-induced bone loss as seen in bedridden patients and among
astronauts that experience a weightless environment.[33] Second, a muscle paralysis model
was used by injecting small volumes of Botulinum toxin A (Botox) in the right hindlimb mus-
culature to paralyze and thus underload this limb. The Botox model may be a better model for
representing localized disuse osteoporosis, as seen in patients with muscular impairment or
spinal cord injury [34]. Finally, we conducted an additional catabolic control experiment to
probe the specificity of Lrp5 HBMmutations in regulating mechanically derived bone wasting
processes, by exposing a set of mice to a non-mechanical (hormonal) catabolic stimulus. The
ovariectomy (OVX) model was used to model post-menopausal bone loss associated with
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estrogen deficiency. Overall, these experiments allowed us to determine whether the Lrp5
HBMmutant receptors confer bone-protective effects in an environment of reduced mechani-
cal stimulation, and whether those effects are different than those yielded by a non-mechanical
bone-wasting stimulus.
Materials and Methods
Mice
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Indiana University Institutional Animal Care and Use Committee (IACUC).
Generation of mice with the high-bone-mass-causing Lrp5 mutations A214V and G171V
knocked-in the Lrp5 locus was described previously [35]. Briefly, two targeting constructs
spanning introns 2–4 were generated, which harbored the p.G171V or p.A214V missense
mutations located in exon 3. The mice were bred to homozygosity (Lrp5+/+, Lrp5A214V/A214V,
or Lrp5G171V/G171V; henceforth deonted as WT, A214V, and G171V, respectively). The genetic
background of all mice was a uniform mixture of 129S1/SvIMJ and C57Bl/6J.
Hindlimb Suspension
Forty-eight 10 week old female mice were enrolled with 16 mice of each Lrp5 genotype (WT,
A214V, G171V) and each genotype further divided into control and hindlimb-suspended mice
(n = 8/group). All mice were individually housed and a tail harness was used to suspend the
experimental mice as previously described.[31] Control mice were permitted unencumbered
normal movement in their cages. Mice received intraperitoneal injections of tetracycline (120
mg/kg) 3 days prior to suspension and calcein (18 mg/kg) 3 weeks later. Mice were suspended
for a total of 24 days prior to sacrifice.
Botulinum toxin-induced muscular paralysis
Twenty-four 16 week old male mice were enrolled with 8 mice of each Lrp5 genotype (WT,
A214V, G171V) The right hindlimb musculature (quadriceps, triceps surae, tibialis anterior,
hamstrings) was injected with 20 μL of Botulinum Toxin A (Botox; Allergan Inc., Irvine, CA),
while the left hindlimb musculature was injected identically with 20 μL of saline to serve as an
internal control [36]. The injections were repeated one week later to ensure paralysis. Mice
received injections of tetracycline (intraperitoneal 60 mg/kg, subcutaneous 60 mg/kg) the day
prior to Botox administration and an intraperitoneal injection of calcein (18 mg/kg) 16 days
later. Mice were sacrificed 22 days after the first Botox injection. Mice were able to access food
and water without difficulty.
Ovariectomy (OVX)
Forty-seven 10 week old female mice were enrolled with 16 mice of the WT and A214V geno-
type and 15 mice of the G171V genotype. Each genotype was further divided into control
(sham) and ovariectomized (ovx) mice (n = 8/group, except n = 7 in G171V ovx group). Mice
received intraperitoneal injections of tetracycline (120 mg/kg) the day prior to surgery and aliz-
arin (20 mg/kg) 3 weeks later. Mice were sacrificed 27 days after surgery. For each mouse, the
uterus was carefully dissected, checked for presence or absence of ovaries, and weighed to
assess for atrophy due to estrogen deficiency.
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Dual energy x-ray absorptiometry (DEXA)
Whole-body in vivo DEXA scans were collected for each experiment on a GE Lunar PIXImus2,
two days prior to the start of the experiment and again at sacrifice. Mice were anesthetized with
isofluorane (2% @ 1.5 liters/min) during the procedure. Whole-body areal bone mineral den-
sity (aBMD) and bone mineral content (BMC) were calculated for the entire post-cranial skele-
ton among mice in the ovariectomy experiment. Femoral aBMD and BMC were measured for
the hindlimb suspension and Botox experiments by adjusting the region of interest box to
accommodate only the femur.
Micro-computed tomography (μCT)
The right femur and 5th lumbar vertebra were extracted at sacrifice to use in μCT analyses
(Skyscan 1172). The bones were placed in 10% NBF for 2 days and then stored in 70% etha-
nol at 4°C. At the time of scanning, the femurs or L5 vertebrae were placed in a tube contain-
ing a thermoreversible gel (Pluronic1 F108) to securely immobilize the bones during the
scan [37]. Acquisition settings were 60 kV, 1000x524 camera size, 0.4° step size, and a resolu-
tion of 10.04 microns/pixel. Trabecular bone was segmented from cortical bone manually
using the Skyscan software package CTAn. The distal femur analysis region was 100 slices
(~1.0 mm) in height and the L5 region encompassed the entire trabecular volume between
growth plates.
Dynamic Histomorphometry
Following microCT measurement, femurs were dehydrated in graded alcohols, cleared in
xylene, and embedded in methylmethacrylate following standard protocols [31]. Thick sec-
tions were cut from the midshaft using a diamond wafering saw, ground down to ~30 μm,
mounted on standard microscope slides, and coverslipped unstained. The femoral sections
were digitally imaged on a fluorescent microscope using filter sets that provide excitation and
emission for the tetracycline, calcein, and alizarin wavelengths. Digital images were imported
into ImagePro Express (Media Cybernetics, Inc., Gaithersburg, MD) and the following histo-
morphometric measurements were recorded for the endosteal and periosteal surface: total
bone perimeter (B.Pm), single label perimeter (sL.Pm), double label perimeter (dL.Pm), dou-
ble label area (dL.Ar), total bone area and marrow area. The following results were calculated:
mineral apposition rate (MAR = dL.Ar/dL.Pm/49 days), mineralizing surface (MS/BS = (0.5
sL.Pm + dL.Pm)/B.Pm100), and bone formation rate (BFR/BS = MAR  MS/BS  3.65). Tis-
sue processing error led to the loss of two slide samples in the Botox experiment (n = 6 for
the G171V mice).
Statistical Techniques
For the tail suspension and OVX studies, pre-intervention and post-intervention DEXA mea-
surements were compared. A paired t-test was used to determine if a difference occurred
between the initial and final measurements within an Lrp5/treatment group. The percent
change of a measurement from initial to final time points for each animal was calculated and
the means of these percent changes were compared using student’s t-test within an Lrp5 geno-
type (between treatments). For microCT and histomorphometry, the values within an Lrp5
genotype were compared using student’s t-test (paired t-test for Botox mice). Statistical signifi-
cance was taken at p< 0.05. Data are presented as mean ± standard devieation.
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Results
Lrp5 G171V and A214V HBMmutations impart partial protection against
tail suspension-induced bone loss
To evaluate the bone-wasting effects of a fluid-shift disuse model applied to Lrp5-HBMmice,
we evaluated the effects of tail suspension on bone mass, density, and structural properties in
Lrp5 WT and HBMmutant mice. Regardless of genotype, all ground control mice gained body
weight, whereas the tail suspended mice did not gain nor lose a significant amount of body
weight (Fig 1A). WT ground control mice maintained femoral aBMD but gained 10%
(p<0.01) of their initial femoral BMC over the duration of the experiment (Fig 1B and 1C).
Tail suspended WTmice lost 10% femoral aBMD (p<0.001) and 4% femoral BMC (p<0.05)
over the course of the experiment. As expected, HBMmutants had significantly greater aBMD
Fig 1. (A) Initial (IN) and final (FI) body weight in ground control (GC) and tail suspended (TS) mice. Percent
change in femoral bone mineral density (B) and content (C) calculated from DEXA scans collected just prior
to the start of the experiment and again at sacrifice. *p<0.05 for tail suspended mice vs genotype-matched
control mice. n = 8/group.
doi:10.1371/journal.pone.0140775.g001
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(25–27%, p<0.001) and BMC (30–46%, p<0.001) compared to WT mice at the start of the
experiment. Both A214V and G171V ground control mice gained a significant amount of
aBMD (10% and 5%, respectively; both p<0.05) and BMC (13%, 11%, respectively; both
p<0.001) over the study duration. Tail suspended A214V and G171V mice exhibited no signif-
icant loss of femoral BMC over the experimental period (change not significantly different
from zero), but G171V mice lost a modest but statistically significant 3% aBMD (p<0.05).
Analysis of distal femur cancellous bone by μCT indicated that tail suspension reduced BV/
TV by 38% (p<0.05), compared to WT ground control mice (Fig 2A and 2G). Consistent with
our earlier reports,[29, 38, 39] the ground control A214V and G171V mice had dramatically
increased distal femur BV/TV, reaching 226% and 219% greater values, respectively (p<0.001)
than the ground control WT control mice. Tail suspension resulted in 24% and 11% lower BV/
TV (p< 0.05) in A214V and G171V mice, respectively, compared to their genotype-matched
ground control relatives (Fig 2A). Trabecular number was significantly reduced in tail sus-
pended WT mice (p<0.05) but not in tail suspended A214V or G171V mice (Fig 2B). Trabecu-
lar thickness was reduced significantly by tail suspension in all three genotypes (p<0.05; Fig
2C). Cancellous parameters in the fifth lumbar vertebral body (L5) followed similar trends as
were observed in the femoral metaphysis (S1 Fig and S1 Table). Midshaft femur cortical area
was significantly reduced by tail suspension in all three genotypes (6–13% reduction, p<0.05;
Fig 2D), whereas medullary area was statistically unchanged by tail suspension in all three
groups (Fig 2E). However, total tissue area at the midshaft was significantly reduced in WT
and A214V mice (5–8% reduction, p<0.01) but not in G171V mice (Fig 2F).
Midshaft femur histomorphometric measurements indicated that all genotypes exhibited a
significant tail-suspension-induced reduction in periosteal MS/BS (30–50%, p<0.05) and peri-
osteal BFR/BS (45–67%, p<0.05) compared to genotype-matched controls (S2 Fig and S2
Table), whereas periosteal MAR was significantly reduced by tail suspension only in the A214
mutants. On the endocortical surface, we found significantly lower MAR (38–59%), MS/BS
(24–50%), and BFR/BS (49–76%) among tail suspended mice from all three Lrp5 genotypes,
compared to their genotyped-matched ground control relatives.
Lrp5 G171V and A214V HBMmutations impart partial protection against
muscle paralysis-induced bone loss
To evaluate the bone-wasting effects of a second model of disuse osteoporosis—one involving
reduced muscle stimulation due to paralysis—in Lrp5-HBMmice, we treated WT and HBM
mice with unilateral hindlimb injection of Botox. To confirm the efficacy of the Botox model,
we first evaluated muscle atrophy using the quadriceps muscle weight in each of the three Lrp5
genotypes. Regardless of genotype, Botox treatment of the right hindlimb musculature was
associated with a 44–51% decrease (p<0.001) in quadriceps weight, compared to the contralat-
eral saline injected quadriceps (Fig 3A). Moreover, the three genotypes lost a statistically equal
amount of total body weight over the experimental period (Fig 3B). Next, we evaluated the
effects of unilateral Botox-induced muscle paralysis on bone mass and density in Lrp5 WT
mice. The femurs of both saline (control) and Botox-injected limbs lost a significant amount of
aBMD and BMC, but the Botox-induced losses (17–23% reduction, p<0.001) were signifi-
cantly greater than those of the saline limb (5–6% reduction, p<0.05; Fig 3C and 3D). In HBM
mice, saline-injected limbs exhibited no significant change in aBMD or BMC, except for a mild
2% reduction (p<0.05) in aBMD among G171V mice. The Botox-injected limbs of HBMmice
lost both femoral aBMD (9% reduction, p<0.01) and BMC (4–5% reduction, p<0.05) over the
study duration, but the paralysis-induced loss of BMC among the HBMmice was not signifi-
cantly different from the loss observed in the saline control limbs (Fig 3).
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Fig 2. μCTmeasurements of cancellous and cortical bone properties in the femur of ground control (GC) and tail suspended (TS) mice. (A) Bone
volume fraction, (B) trabecular number, and (C) trabecular thickness were measured in the distal femur metaphysis. (D) Cortical area, (E) medullary area,
and (F) total tissue area were measured in the mid-diaphyseal femur. (F) Representative μCT reconstructions of the distal femur from GC ad TS mice within
each genotype. The anterior and posterior thirds of each reconstruction have been removed digitally to reveal the metaphyseal spongiosa. *p<0.05 for tail
suspendedmice vs genotype-matched control mice. n = 8/group.
doi:10.1371/journal.pone.0140775.g002
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Analysis of distal femur cancellous bone by μCT indicated that among WT mice, Botox
reduced BV/TV by 35% (p<0.01), compared to the saline-injected control limb (Fig 4A).
A214V and G171V mice exhibited significant but milder Botox-induced reductions in BV/TV
(8% and 12% reduction, respectively, p<0.05). Trabecular number was significantly reduced
(26% reduction, p<0.01) by Botox in WT mice but not in either HBMmutant line (Fig 4B).
Trabecular thickness was significantly reduced by Botox treatment in WT mice (13% reduc-
tion, p<0.01) and in A214V and G171V mice (6% and 9% reduction, respectively, p<0.05; Fig
4C). Analysis of the midshaft femur cortex revealed no significant Botox-induced changes in
medullary area (Fig 4E) or total tissue area (Fig 4F) for any of the three genotypes. However,
cortical area was significantly reduced in WT mice (6% decrease, p<0.05) but not in either
HBM line (Fig 4D).
Fig 3. (A) Quadriceps muscle mass was decreased in the botox-injected (BX) limb compared to the saline-
injected (SL) limb, among all genotypes. (B) Initial (IN) and final (FI) body weight was similar among all three
genotypes. Percent change in femoral bone mineral density (B) and content (C) calculated from DEXA scans
collected just prior to the start of the experiment and again at sacrifice. * p<0.05 for botox-treated limb vs.
saline-treated limb within genotype. n = 8/group, except for WT quadriceps mass (n = 7) due to tissue
collection error.
doi:10.1371/journal.pone.0140775.g003
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Fig 4. μCTmeasurements of cancellous and cortical bone properties in the femur frommice that underwent intramuscular injection of saline (SL)
into the left lower limb and botox (BX) into the right lower limb. (A) Bone volume fraction, (B) trabecular number, and (C) trabecular thickness were
measured in the distal femur metaphysis. (D) Cortical area, (E) medullary area, and (F) total tissue area were measured in the mid-diaphyseal femur. (F)
Representative μCT reconstructions of the distal femur from SL- ad BX-treated limbs within each genotype. The anterior and posterior thirds of each
reconstruction have been removed digitally to reveal the metaphyseal spongiosa. *p<0.05 for botox-treated limb vs. saline-treated limb within genotype.
n = 8/group.
doi:10.1371/journal.pone.0140775.g004
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Dynamic histomorphometric measurements from the midshaft femur endocortex revealed
that the WT mice exhibited a significant Botox-induced reduction in MS/BS (-55%, p<0.01)
and BFR/BS (-62%, p<0.05), with no significant change in MAR (S3 Fig, S3 Table). Conversely,
both HBMmouse strains exhibited no significant Botox-induced change in any of the endocor-
tical measurements collected. The periosteal surface exhibited few differences between Botox-
treated and saline-treated limbs (S3 Table).
Lrp5 HBMmutations reduce ovariectomy-induced bone loss
Having found that two different mechanically-based bone wasting stimuli had milder or nulli-
fied effects for some bone properties among HBMmice, we sought to learn whether the osteo-
protective effects of those mutations were active in nonmechanical bone-wasting contexts.
Therefore, we performed ovariectomy (OVX) surgeries in WT, A214V, and G171V mice and
measured the skeletal response. To confirm the efficacy of the ovariectomy (OVX) model in
our experiments, we first evaluated changes in uterus weight in ovariectomized and sham-
operated mice. Regardless of genotype, OVX was associated with a 74–80% decrease (p<0.01),
in the uterus weight:body weight ratio, compared to genotype-matched sham-operated animals
(Fig 5A), indicating a successful reduction in estrogen levels via surgical intervention (ovary
removal). Moreover, the three genotypes gained a similar amount of total body weight over the
experimental period (Fig 5B). Next, we evaluated the effects of ovariectomy on whole-body
bone mass and density. WT sham-operated mice exhibited no significant change in aBMD or
BMC over the study duration (Fig 5C and 5D). OVX in WTmice resulted in a significant loss
of whole body aBMD (-5%; p<0.01) and BMC (-8%; p<0.05). Both A214V and G171V mice
subjected to sham surgery gained a significant amount of whole body aBMD (+5% and +3%,
respectively, p<0.05), though only A214V sham-operated gained BMC (+6%, p<0.001).
OVXed A214V and G171V mice exhibited no significant changes in whole body aBMD or
BMC over the duration (change not significantly different from zero), with the exception of the
G171V mice, which lost -4% aBMD (p<0.01).
In the distal femur metaphysis, OVXed WT mice exhibited significantly lower BV/TV (35%
reduction, p<0.05) compared to sham (Fig 6A). OVX resulted in a -27% and -15% lower BV/
TV (p<0.05) in A214V and G171V mice, respectively. Trabecular number was significantly
reduced by OVX in all three genotypes (33, 19, and 12% reductions in WT, A214V, and
G171V, respectively; p<0.05, Fig 6B). Trabecular thickness was reduced by OVX only in the
A214V mice (Fig 6C). Cancellous parameters in the fifth lumbar vertebral body (L5) revealed
that the G171V mutation was protective against OVX-induced trabecular bone loss (S4 Fig and
S4 Table). The OVX procedure in WT mice resulted in significantly reduced BV/TV, Tb.N,
and Tb.Sp, whereas the same outcomes were not altered in OVXed G171V mice. A214V mice
exhibited a significant OVX-induced loss of BV/TV and Tb.N. Midshaft femur cortical area
was significantly reduced by OVX in WT (7% reduction, p<0.05) but not A214V or G171V
mice (Fig 6D). Medullary area and total tissue area were statistically unchanged by OVX in all
three groups (Fig 6E and 6F), though the OVX-induced reduction in total tissue area among
WTmice approached statistical significance (p = 0.06).
Evaluation of midshaft femur histomorphometric indices from the periosteal and endocorti-
cal surfaces yielded no significant differences within any Lrp5 genotype as a result of OVX (S5
Fig and S5 Table).
Discussion
We initiated a set of osteocatabolic experiments to determine if the LRP5 high bone mass
(HBM) missense mutations, A214V and G171V, have protective effects on the bone wasting
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response to mechanical disuse in the growing and mature mouse skeleton. We subjected LRP5
HBM knock-in mice to two different models of disuse osteoporosis—tail suspension and mus-
cle paralysis. As a control experiment, we subjected HBMmice to a non-mechanical bone wast-
ing stimulus—ovariectomy (OVX). In both disuse models, we observed differences in our
endpoints between bones from the control animal/leg and the mechanically deprived animal/
leg, indicating that disuse affects the skeleton to some degree in HBMmice, albeit to a lesser
extent than in WTmice. The question of whether the HBM alleles can prevent disuse induced
bone loss per se (as opposed to the separate question of whether disuse affects bone accumula-
tion), can only be addressed using the DEXA data, where we have measurements of lower limb
Fig 5. (A) The ratio of uterus wet weight to total body weight was decreased in the mice that underwent
ovariectomy surgery (Ov) compared to sham-operated (Sh) littermates, among all genotypes. (B) comparison
of initial (IN) and final (FI) body weight was similarly increased among all three genotypes as a result of OVX.
Percent change in whole body bone mineral density (B) and content (C) calculated from DEXA scans
collected just prior to the start of the experiment and again at sacrifice. * p<0.05 Ovx vs. sham within
genotype. n = 8/group, except for G171Vmice (n = 7).
doi:10.1371/journal.pone.0140775.g005
Lrp5 HBM Alleles Reduce Disuse-Induced Bone Loss
PLOS ONE | DOI:10.1371/journal.pone.0140775 November 10, 2015 11 / 18
Fig 6. μCTmeasurements of cancellous and cortical bone properties in the femur frommice that underwent ovariectomy surgery (Ov) or sham
surgery (Sh). (A) Bone volume fraction, (B) trabecular number, and (C) trabecular thickness were measured in the distal femur metaphysis. (D) Cortical area,
(E) medullary area, and (F) total tissue area were measured in the mid-diaphyseal femur. (F) Representative μCT reconstructions of the distal femur from
OVX- and sham-operated mice within each genotype. The anterior and posterior thirds of each reconstruction have been removed digitally to reveal the
metaphyseal spongiosa. *p<0.05 for OVX vs. sham within genotype. n = 8/group, except for G171Vmice (n = 7).
doi:10.1371/journal.pone.0140775.g006
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bone mass prior to disuse, and again after 3 wks of disuse. Those measurements indicate that
the HBM alleles are able to prevent, or nearly prevent, the disuse-induced bone loss seen in
WT animals. For example, tail suspension treatment resulted in a significant ~4% decrease in
femoral BMD among WT mice, whereas HBMmice exhibited no change, or a significant
increase, in femur BMC as a result of tail suspension. A similar picture emerges for the Botox
experiment: Botox treatment resulted in a significant ~23% decrease in femur BMC among
WTmice, whereas the same treatment applied to HBMmice resulted in a modest 4–5%
decrease in femur BMC. While that decrease in bone properties among HBMmice is signifi-
cant, it is several-fold less than that observed for WT mice. Taken together, these data suggest
that the HBM alleles confer significant, nearly complete, protection from bone loss associated
with disuse.
The μCT data from the distal femur and lumbar spine indicate significant and roughly
equal disparities between control bones and disuse-treated bones, suggesting that trabecular
bone is susceptible to disuse effects whether HBM orWT alleles are present. While these results
may appear to contradict the serial BMC data discussed above, the μCT parameters are single
endpoints and are unable to reflect changes in the trabecular parameters over time (i.e. whether
the trabecular bone was maintained or reduced in the suspended mice). Assessment of actual
trabecular bone loss, rather than a failure to gain bone, would require an additional baseline
control group for each genotype that was sacrificed on the day that disuse was induced. Thus it
is unclear whether disuse induced significant trabecular bone loss in the HBMmice, or
whether, like the DEXA data highlight for the whole leg, those mice failed to continually
increase their trabecular bone during the experimental period (as might have occurred in the
saline-treated limb). From a functional perspective, the trabecular bone parameters in HBM
suspended mice were consistently greater than those of WT control mice, indicating that the
HBMmutants were, at the very least, partially protected from suspension-induced osteopenia
during the study and were able to still maintain a HBM phenotype.
Using a loss-of-function mouse model of Lrp5 signaling, we previously reported that
mechanical (ulnar loading) but not hormonal (intermittent PTH) stimuli are compromised by
a lack of Lrp5 expression [40]. Likewise, preliminary experiments in an Lrp5 gain-of-function
transgenic mouse model (3.6kbColIa1::Lrp5G171V) show that mechanical (sciatic neurectomy)
but not hormonal (OVX) challenges are associated with preserved bone mass when G171V is
overexpressed [41]. To assess whether the bone-sparing effects of Lrp5 HBM alleles are mani-
fest in catabolic conditions other than mechanical disuse in our models, we exposed the HBM
andWT mice to the hormonal challenge of estrogen deprivation via OVX. We found that
whereas the WT mice exhibited significant losses in whole body aBMD and BMC as a result of
OVX, the HBMmice were largely protected from those losses. Similar to the disuse studies, the
OVX mice had less trabecular bone in the femur and spine than the sham-surgery mice,
regardless of Lrp5 genotype. An exception to this trend was among the G171V mice, which
exhibited protection from OVX-induced trabecular bone effects in most of the μCT measure-
ments made. Again, it is unclear whether the trabecular bone in the A214V mice was protected
from loss, or if failure to gain bone during the experimental period can account for the discrep-
ancies. In either case, the bone-protective effects of Lrp5 HBM alleles are not restricted to
mechanical challenges, but also appear to be active in estrogen-deficient environments.
We have previously found that both HBMmutations are protected from the bone loss
induced by Sost overexpression. It has also been reported that tail-suspension induced bone
loss is mediated by an increased expression of Sost, and that genetic deletion of Sost or anti-
body-mediated inhibition of sclerostin prevents suspension-induced bone loss [18, 42]. We
report here in our two disuse experiments that the HBMmutations protect against disuse-
induced cortical bone loss, but are unable to maintain normal (accelerated) bone growth
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associated with the HBM alleles. These observations present a potential conundrum: Sost-/-
mice are completely immune to disuse effects in bone, yet the sclerostin-resistant Lrp5 HBM
mice only maintain bone during disuse.
Several possibilities can be invoked to explain this discrepancy. First, while Sost is required
to mediate disuse-induced bone loss, another signaling component may also be required, such
as a corresponding decrease in Wnts. In this scenario, disuse in WT mice results in reduced
Wnt and increased Sost (which might then fully suppress Wnt signaling), while disuse in HBM
results in similarly reduced Wnt expression without being affected by the increased Sost (thus
allowing someWnt signaling that allows maintenance of bone mass). Another possible expla-
nation is that disuse-induced Sost expression may be increased to a higher extent than that
caused by 8kbDmp1::Sost overexpression (i.e., 8kbDmp1::Sost mouse is not a phenocopy of a
tail-suspended mouse), thereby allowing sclerostin to suppress Lrp5 signaling to a fuller extent
than is seen in the overexpression model. Alternatively, the effects might be related to scleros-
tin’s other targets, including Lrp6 and Lrp4. In the Sost-/- mice, both Lrp5 and Lrp6 would be
expected to experience Wnt signaling uninhibited by sclerostin, whereas in our Lrp5 HBM
knock-ins, Lrp6 would be expected to experience the full effects of sclerostin-mediated inhibi-
tion of that receptor. Further, it is unclear how these mutations affect the expression of or inter-
action with a recently identified cofactor—Lrp4—for sclerostin’s inhibitory action on Lrp5/6
signaling [43–45].
While the disuse experiments we report support a consistent theme of reduced bone loss in
HBMmice, there are some discrepancies between the two models. First, it should be noted that
the Botox injections were performed on 16-wk-old mice and the hindlimb suspension experi-
ments were performed on a 10-wk-old mice, so comparison between these two models is not
truly a direct one due to the confounding effects of growth in the hindlimb suspension studies.
Second, we did detect a small systemic effect (i.e., in the saline-injected left leg) induced by local
Botox injections in the right leg musculature. Comparison of the DEXA-derived changes in bone
mass in the ground control mice from the tail suspension experiment, with DEXA-derived
changes in bone mass in the saline-treated leg of the Botox animals reveals a noticeable suppres-
sion of bone gain in the presence of contralateral Botox exposure. Similar observations have been
reported previously [46], but it is unclear whether this effect is fueled by Botox compound enter-
ing the systemic circulation and modestly suppressing muscle function elsewhere in the body, or
perhaps by reducing overall mobility (normal functional loading in the control leg) because of
the contralateral paralysis. The use of two disuse models has a clear advantage in overcoming the
experimental limitations of either model, and in our case, has added considerable strength to the
observation that the HBM alleles have a protective effect on disuse-induced bone loss.
Previous reports on ovariectomy in the transgenic HBMmouse, 3.6kbCol1a1::Lrp5G171V,
indicated that the mice lost bone at the same rate as WT mice, suggesting that they were not
protected from bone loss due to sex hormone deficiency [41]. However, the same mouse model
was protected from sciatic neurectomy induced bone loss [47]. We found that the HBM
knock-in mice were much less affected by OVX than their WT controls. Although our disuse
experiments were conducted on mice of differing age (16 wks for botox experiments vs 10 wks
for tail suspension [and OVX]), the differences in response to challenge in out mice might be
due to genetic engineering differences between the models (e.g., knock-in strategy versus the
transgenic approach). Our knock-in model expresses Lrp5 according to the endogenous spa-
tial–temporal profile and is not limited to or enhanced by expression of the 3.6kbColIa1 pro-
moter. We found that although our HBMmice were unable to accrue bone (compare to
shams), they did not significantly lose aBMD or BMC over time, with the exception of one
measurement. These results highlight the potential therapeutic value of targeting this pathway
pharmacologically in order to prevent menopause induced bone loss.
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In conclusion, these results give support to the hypothesis that the Lrp5 HBMmutations
protect against bone loss in the presence of bone wasting stimuli. We found that the disuse sti-
muli induced significant bone loss in WT mice, but Lrp5 A214V and G171V were partially or
fully protected from the bone loss that normally results from disuse. Trabecular bone parame-
ters among HBMmice were significantly affected by disuse in both models, but these data are
consistent with DEXA data showing a failure to continue growing in HBMmice, rather than a
loss of pre-existing bone. Surprisingly, ovariectomy in Lrp5 HBMmice resulted in similar pro-
tection from bone catabolism. The Lrp5 HBM alleles offer significant protection from the cata-
bolic effects of disuse and estrogen deficiency, and consequently, present a potential
mechanism to target pharmacologically to protect against various bone-wasting stimuli.
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S1 Fig. Representative μCT reconstructions of the fifth lumbar vertebra from GC and TS
mice within each genotype. The anterior and posterior thirds of each reconstruction have
been removed digitally to reveal the vertebral body spongiosa. See S1 Table for fifth lumbar ver-
tebral cancellous measurements.
(TIF)
S2 Fig. Representative fluorochrome-labeled midshaft femur sections from ground control
(GC) and tail suspended (TS) mice.Macro-scale images of the entire cross section are shown
to the left, and close-up panels of the areas indicated by the white boxes are shown at higher mag-
nification to the right. Although several fluorochromes were injected to monitor bone formation,
data were collected using the pretreatment label (tetracycline, indicated by gold arrow) and the
calcein label (green arrow), which was given close to the sacrifice date. The tetracycline label is
not as strong as the other labels and is difficult to visualize in many of the photomicrographs.
(TIF)
S3 Fig. Representative fluorochrome-labeled midshaft femur sections from the saline-treated
limb and the botox-treated limb.Macro-scale images of the entire cross section are shown to
the left, and close-up panels of the areas indicated by the white boxes are shown at higher magni-
fication to the right. Although several fluorochromes were injected to monitor bone formation,
data were collected using the pretreatment label (tetracycline, indicated by gold arrow) and the
calcein label (green arrow), which was given close to the sacrifice date. The tetracycline label is
not as strong as the other labels and is difficult to visualize in many of the photomicrographs.
(TIF)
S4 Fig. Representative μCT reconstructions of the fifth lumbar vertebra from OVX- and
sham-operated mice within each genotype. The anterior and posterior thirds of each recon-
struction have been removed digitally to reveal the vertebral body spongiosa. See S4 Table for
fifth lumbar vertebral cancellous measurements.
(TIF)
S5 Fig. Representative fluorochrome-labeled midshaft femur sections from OVX- and
sham-operated mice.Macro-scale images of the entire cross section are shown to the left, and
close-up panels of the areas indicated by the white boxes are shown at higher magnification to
the right. Although several fluorochromes were injected to monitor bone formation, data were
collected using the pretreatment label (tetracycline, indicated by gold arrow) and the alizarin
label (red arrow), which was given close to the sacrifice date. The tetracycline label is not as
strong as the other labels and is difficult to visualize in many of the photomicrographs.
(TIF)
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